<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0012115'>Hepatitis</z:hpo>-associated <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (HAA) is characterized by marrow failure developing after <z:hpo ids='HP_0011009'>acute</z:hpo> seronegative <z:hpo ids='HP_0012115'>hepatitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A patient with <z:hpo ids='HP_0004432'>agammaglobulinemia</z:hpo> developed HAA in association with HBsAg-negative, <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B virus (HBV) DNA-positive <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Sequence analysis showed several substitutions in the major antigenic determinant of HBsAg, potentially affecting the detection by diagnostic immunoassays </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0001799'>Viral</z:mp> mutants may therefore be implicated as etiologic agents of HBsAg-negative HAA </plain></SENT>
<SENT sid="4" pm="."><plain>HBV DNA determination may be necessary to exclude mutant HBV as a cause of HAA, particularly in categories at high risk of mutant selection such as agammaglobulinemic and transplanted patients </plain></SENT>
</text></document>